| |
Digital transformation, AI, big data, and regulatory action—these four trends are shaping the healthcare industry. From new technologies to billion-dollar research funding, there are plenty of lucrative investment opportunities to be had. Learn more.
|
|
Today’s Big NewsAug 24, 2023 |
|
October 16-17 | Boston, MA
Effectively drive collaboration between R&D, clinical and commercial teams to develop an appropriate timeline and practical approach to bringing new products to launch. Book your seat today and save $200!
|
|
| By Nick Paul Taylor Roche has provided fresh evidence that its KRAS inhibitor divarasib is a threat to Amgen and Mirati. The results of an early-phase monotherapy clinical trial suggest divarasib may improve on the response rate and durability of its more advanced rivals, but the jury remains out for now. |
|
|
|
By Zoey Becker Exelixis' drug proved its worth in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors, so much so that an independent board unanimously recommended an early stop. |
By Conor Hale Both companies hope their approaches will enter a multibillion-dollar market, as each looks to offer a drug-free procedure that makes a dent in stubbornly high blood pressure. |
By Kevin Dunleavy Cell therapy manufacturing innovator Cellares has revealed a $255 million series C investment round to complete construction of its facility in Bridgewater, New Jersey. One of the investors is major cell therapy player Bristol Myers Squibb. |
By Andrea Park For the fourth time this year, German devicemaker Dräger’s portfolio of respiratory devices is the target of a recall deemed Class I by the FDA. |
By James Waldron Don’t count on the triumphant return of biotech SPAC deals quite yet. Despite Wilbur Ross’ own blank check company making one of the first SPAC announcements for the sector this year, it turns out that deal has now died. |
By Fraiser Kansteiner After the “extreme disappointment” of vadadustat’s anemia snub in March 2022—plus a partnership gone awry and a formal dispute with the FDA—Akebia Therapeutics has dusted itself off and readied for a second bid at approval. |
By Max Bayer Given the challenges of running an efficacy study for a group B streptococcus (GBS) vaccine, Pfizer's top vaccine executive hopes that regulators will allow an immunogenicity study for approval instead, just as they have for the New York pharma's meningitis B and pneumococcal vaccines. |
By Kevin Dunleavy Royalty Pharma has signed a deal with Ferring Pharmaceuticals to collect royalties on bladder cancer drug Adstiladrin. Royalty will pay $300 million up front and $200 million in a potential milestone tied to Ferring meeting certain manufacturing goals. New York City-based Royalty will receive 5.1% of net sales of Adstiladrin in the U.S. Upon payment of the milestone, the royalty will jump to 8%. |
By Andrea Park The GuideMe software is meant to speed up the patient training process and make it easier while also giving users more confidence as they transition from in-clinic to at-home dialysis sessions. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now.
|
|
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
